Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
Ariad Pharmaceuticals
D Ross Camidge; Hye Ryun Kim; Myung-Ju Ahn; James C H Yang; Ji-Youn Han; Maximilian J Hochmair; Ki Hyeong Lee; Angelo Delmonte; Maria Rosario García Campelo; Dong-Wan Kim; Frank Griesinger; Enriqueta Felip; Raffaele Califano; Alexander Spira; Scott N Gettinger; Marcello Tiseo; Huamao M Lin; Neeraj Gupta; Michael J Hanley; Quanhong Ni; Pingkuan Zhang; Sanjay Popat